您当前所在位置:首页 > 材料科学 > 新品上市
序号 标题 次数 作者 发布时间
75781 FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne 125 WYQ 2024-12-19
75782 DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 81 h 2024-12-19
75783 CAS: 2762518-86-3 ,NHS ester-PEG4-Val-Cit-PAB-MMAE 94 WYQ 2024-12-19
75784 cas:2873452-49-2 ; MC-EVCit-PAB-MMAE,ADC定制 114 wyh 2024-12-19
75785 CAS: 2762519-08-2 endo-BCN-PEG4-Val-Cit-PAB-MMAE,内末端二苯卡宾吡啶甲酸乙酯聚乙二醇4个单元赖氨酸缬氨酸丙氨酸天冬氨酸 131 WYQ 2024-12-19
75786 cas:863971-24-8,Mc-MMAE ,马来酰亚胺基己酰-单甲基澳瑞他汀 E 168 kx 2024-12-19
75787 DOTA-(AEEA)2-BN DOTA-(AEEA)2-铃蟾肽 84 h 2024-12-19
75788 cas:2259318-55-1 , DBCO-(PEG2-VC-PAB-MMAE)2,ADC定制 96 wyh 2024-12-19
75789 cas:1394238-91-5 Fmoc-Val-Ala-PAB 115 zyl 2024-12-19
75790 CAS: 2285373-84-2 Ethyl (S)-1-((1-((4-((((4-nitrophenoxy)carbonyl) oxy)methyl)phenyl)amino)-1-oxo-5-ureidopenta n-2-yl)carbamoyl)cyclobutane-1-carboxylate 136 WYQ 2024-12-19
75791 Azido-Phenyl-Amido-SS-Sulfo-NHS Ester, ADC试剂 100 kx 2024-12-19
75792 DOTA-βala-K-NOTA-BBN(7-14)NH2 112 h 2024-12-19
75793 DBCO-PEG3-acetic-Val-Cit-PAB,主要用于合成抗体偶联药物(ADC) 93 WYQ 2024-12-19
75794 Mal-PEG4-Val-Ala-PAB-PNP,ADC定制 73 wyh 2024-12-19
75795 cas:330970-70-2 Alloc-Val-Ala-OH 90 zyl 2024-12-19
75796 DOTA-somatostatin receptor analogs DOTA生长抑素受体类似物 72 h 2024-12-19
75797 CAS: 2754384-60-4,DBCO-(PEG)3-VC-PAB-MMAE 74 WYQ 2024-12-19
75798 Fmoc-Gln(Trt)-PAB-OH, ADC试剂 118 kx 2024-12-19
75799 CAS: 2994332-18-0 ,DBCO-C4-Val-Cit-PABC-PNP,二苯并环辛炔-C4-缬氨酸-瓜氨酸-PABC-对硝基苯基磷酸酯 84 WYQ 2024-12-19
75800 cas:159857-60-0,Fmoc-Lys(MMt)-OH,N-[(9H-芴-9-基甲氧基)羰基]-N'-[(4-甲氧基苯基)二苯基甲基]-L-赖氨酸 174 kx 2024-12-19
75801 DBCO-PEG3-Val-Cit-PAB-PNP,二苯并环辛炔-三聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP 119 WYQ 2024-12-19
75802 NOTA-anti-HER2 NOTA标记抗人表皮生长因子受体2型(HER2)纳米体 113 h 2024-12-19
75803 cas:186023-44-9 Fmoc-Ala-Pro-OH 105 zyl 2024-12-19
75804 TCO-PEG4-Val-Cit-PAB-PNP,反式环辛烯-四聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP 87 WYQ 2024-12-19
75805 Boc-Val-Cit CAS:870487-08-4 104 zyl 2024-12-19
75806 DOTA-Bn-FGK-Fab DOTA标记抗体片段 106 h 2024-12-19
75807 cas:252554-78-2,Fmoc-Ala-Ser (Psi(Me,Me)pro)-OH,(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 63 kx 2024-12-19
75808 DOTA-Nal3-Octreotide DOTANOC DOTA-Nal3-奥曲肽 101 h 2024-12-19
75809 cas:2413428-36-9,MC-Gly-Gly-Phe-Gly,(S)-5-苄基-18-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-4,7,10,13-四氧代-3,6,9,12-四氮杂十八烷-1-酸 85 kx 2024-12-19
75810 MC-Val-Cit-PAB-PNP CAS:159857-81-5 131 zyl 2024-12-19
75811 cas:2353409-52-4,Mal-amido-PEG8-Val-Gly-PAB-OH,马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY-PAB-羟基 72 kx 2024-12-19
75812 Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 77 zyl 2024-12-19
75813 cas:1895916-22-9,MC-Val-Ala-OH, ADC试剂 71 kx 2024-12-19
75814 cas:159857-70-2,MC-Val-Cit-Doxorubicin,MC-VAL-CIT-阿霉素 65 kx 2024-12-19
75815 DOTA−Gal-NAPamide DOTA−Gal-纳帕胺 75 h 2024-12-19
75816 DOTA-peptide-Lym-1 radioimmunotherapy DOTA-肽-Lym-1 87 h 2024-12-19
75817 N-DBCO-N-bis(PEG2-amide-PEG4-Val-cit-PAB-MMAE), N-二苯并环辛炔-N-双(二聚乙二醇-酰胺-四聚乙二醇-VAL-CIT-PAB-MMAE) 99 kx 2024-12-19
75818 DOTA-dGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 111 h 2024-12-19
75819 DOTA-MGO DOTA-DGlu-(Glu)s-minigastrin 80 h 2024-12-19
75820 cas:2762518-86-3,NHS Ester-PEG4-Val-Cit-PAB-MMAE, ADC试剂 128 kx 2024-12-19
75821 DOTA-scFv-anti-PSMA DOTA-scFv-抗PSMA脂质纳米粒(LNPs) 82 h 2024-12-19
75822 cas:2353409-45-5,BCN-PEG3-Val-Cit-PFP Ester, ADC试剂 75 kx 2024-12-19
75823 cas:2112738-13-1,Mal-amido-PEG2-Val-Cit-PAB-PNP, ADC试剂 78 kx 2024-12-19
75824 cas:2055041-39-7,Mal-PEG4-Val-Cit-PAB-OH, ADC试剂 74 kx 2024-12-19
75825 cas:2055024-62-7,NH2-PEG3-Val-Cit-PAB-OH, ADC试剂 127 kx 2024-12-19
库存查询